Abstract: The present invention relates to compounds of Formula I, pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I increase significantly low density lipoprotein receptor and are useful for preventing and treating of elevated cholesterol.
Type:
Grant
Filed:
May 23, 2022
Date of Patent:
March 19, 2024
Assignee:
Montréal Heart Institute
Inventors:
Steve Poirier, Brent Richard Stranix, Gaétan Mayer
Abstract: The present invention relates to compounds of Formula I, pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I increase significantly low density lipoprotein receptor and are useful for preventing and treating of elevated cholesterol.
Type:
Grant
Filed:
October 30, 2018
Date of Patent:
August 2, 2022
Assignee:
Montréal Heart Institute
Inventors:
Steve Poirier, Brent Richard Stranix, Gaétan Mayer
Abstract: A method for treating valvular stenosis. The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal. Most preferred is an Apolipoprotein A-1 mimetic peptide/phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.
Abstract: The present invention relates to the use of the dye methylene blue (MB) or a related compound to prevent or reverse an exaggerated hemodynamic reaction in animals in need thereof, including humans. More specifically, the present invention concerns the use of MB or a related compound to prevent or reverse hypotension, unstable angina, myocardial infarction or shock caused by the concomitant ingestion of a phosphodiesterase inhibitor, such as sildenafil citrate, and a NO-donor, such as L-arginine, or an organic nitrate, such as nitroglycerin.
Type:
Grant
Filed:
March 28, 2003
Date of Patent:
January 29, 2008
Assignee:
Montreal Heart Institute
Inventors:
Martin Juneau, Jean-François Tanguay, Denis Brouillette
Abstract: The present invention relates to methods and compositions for the modulation of restenosis and stenosis characterized by constrictive vascular remodeling and neointimal formation, in a subject, by administering a P-selectin antagonist. The invention further provides methods for modulating leukocyte recruitment, cell to cell adhesion, and cell adhesion to blood vessels in a subject by administering soluble P-selectin ligand, an anti-P-selectin ligand antibody, or an anti-P-selectin antibody. The invention also provides methods for identifying compounds capable of modulating restenosis.
Type:
Application
Filed:
May 7, 2003
Publication date:
May 6, 2004
Applicants:
Genetics Institute, LLC, Montreal Heart Institute of Montreal
Inventors:
Anjali Kumar, Robert G. Schaub, Jean-Francois Tanguay, Yahye Merhi